Incyte Inc. has several relevant cancer drugs in its portfolio. Initially, Incyte will support IMPRESS with its drug Pemazyre.
Pemazyre is a targeted drug that attacks fibroblast growth factor receptor 2 (FGFR2). The drug is currently approved for use in adults with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. FGFR2 fusions / rearrangements are strong drivers of cancer development. In IMPRESS-Norway we will be able to test the effect of Pemazyre on patients with other cancers forms with similar FGFR2 alterations. We are very pleased to include Pemazyre in our drug portfolio.
When we include new drugs, we go back and reanalyze the molecular profile of the tumor for patients who have already been discussed at the national molecular tumor board. If a relevant match is found, then we will contact the treating oncologist to see if the new treatment alternative is relevant for the patient.